HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

ropinirole (Requip)

dopamine D2 receptor agonist; structure given in first source; RN given refers to parent; USAN name is ropinirole hydrochloride

Also Known As:

Requip; 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone; GlaxoSmithKline brand of ropinirole hydrochloride; SK&F 101468; SK&F-101,468; SKF 101468; SmithKline Beecham brand of ropinirole hydrochloride; ropinirol; ropinirole hydrochloride

Networked: 322 relevant articles (49 outcomes, 105 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Indoles: 95
    - ropinirole: 322

Experts

1.	Hauser, Robert A: 7 articles (05/2011 - 07/2003)
2.	Rascol, Olivier: 6 articles (10/2011 - 07/2003)
3.	Lyons, Kelly E: 6 articles (05/2010 - 07/2004)
4.	Asgharian, Afsaneh: 5 articles (01/2016 - 09/2008)
5.	Bonuccelli, Ubaldo: 5 articles (11/2014 - 12/2003)
6.	Stocchi, Fabrizio: 5 articles (03/2014 - 07/2003)
7.	Poewe, Werner: 5 articles (08/2012 - 08/2006)
8.	Pahwa, Rajesh: 5 articles (05/2010 - 07/2004)
9.	Lang, Anthony E: 5 articles (12/2007 - 01/2002)
10.	Reichmann, H: 5 articles (10/2005 - 09/2000)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 07/01/2000 - "In the symptomatic treatment of early Parkinson's disease ropinirole monotherapy was significantly more effective than placebo in 2 multicentre, randomised, double-blind trials of 3 to 12 months duration as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and Clinical Global Impression/Clinical Global Evaluation Scales. " 11/01/2013 - "Efficacy outcomes including Unified Parkinson's disease Rating Scale and PDQ-39 subscales of mobility were significantly improved in the ropinirole PR versus placebo group. " 10/15/2007 - "The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). " 07/02/2013 - "The efficacy of ropinirole was assessed with the unified Parkinson's disease rating scale (UPDRS) score, "off" time according to the patient's diary and the overall evolution of clinical efficacy. " 07/02/2013 - "Ropinirole is both effective and safe in the treatment of Chinese patients with Parkinson's disease."
2.	Dyskinesias (Dyskinesia) 07/01/1997 - "Ropinirole has demonstrated efficacy in two standard preclinical models of PD and has shown a very low propensity to induce dyskinesia in these studies. " 01/01/2011 - "Patients receiving ropinirole prolonged release had a significantly greater increase in amount/percentage of awake time "on"/"on" without troublesome dyskinesia during all periods assessed (including night-time and early morning), versus placebo, and higher odds for being "on" on waking. " 09/01/2000 - "Chronic administration of ropinirole for 21 days produced a statistically significant increase in motor activity compared to the initial administration, and akinesia scores, measured through rating the quality of movements, were also improved without obvious dyskinesia. " 09/01/2008 - "In addition to controlling motor symptoms, ropinirole improved both anxiety and depressive symptoms in PD patients with motor fluctuations and/or dyskinesias. " 05/01/2006 - "In the numerous clinical trials that were carried out, it would seem clear that ropinirole can be administered for years as sole early treatment for PD and that it offers a notable reduction in the appearance of dyskinesias. "
3.	Restless Legs Syndrome (Restless Legs) 01/01/2004 - "Symptoms of restless legs syndrome (RLS) [measured using the International Restless Legs scale and Clinical Global Impression-Global Improvement Scale scores] significantly improved with ropinirole compared with placebo in large, randomised, double-blind trials. " 09/01/2006 - "Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. " 10/01/2006 - "Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial." 12/01/2004 - "Ropinirole is effective in the treatment of restless legs syndrome. " 10/01/2006 - "The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. "
4.	Nausea 01/01/2001 - "Withdrawal rates and adverse event frequency were similar with the two agents apart from significantly less nausea with ropinirole (odds ratio 0.50; 0.29, 0.84 95% CI; p =0.01). " 01/01/2000 - "Withdrawal rates and adverse event frequency were similar with the two agents apart from significantly less nausea with ropinirole (odds ratio 0.50; 0.29, 0. " 03/01/1998 - "Although the dopaminergic side effects were reported significantly more frequently in the ropinirole group than in the placebo group (dizziness, p = 0.0326; nausea, p = 0.001; and somnolence, p = 0.005), none necessitated study withdrawal. " 01/01/2004 - "Few patients receiving ropinirole withdrew from therapy because of adverse events, the most predominant of which were nausea and headache." 07/01/2000 - "Nausea, dizziness and somnolence were the most commonly reported adverse events and were reported at a higher incidence by patients receiving ropinirole than by those receiving placebo. "
5.	Tremor (Tremors) 05/01/2002 - "These results suggest that ropinirole monotherapy is effective in treating resting tremor in early PD. " 10/01/2005 - "This is the first prospective study which demonstrates beneficial effects of ropinirole on PD tremor. " 05/01/2002 - "Improvements in resting tremor were significantly better with ropinirole than placebo. " 01/01/2014 - "A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. " 05/01/2002 - "The effect of Ropinirole on tremor in early Parkinson's disease (PD) was assessed. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Dopamine Agonists (Dopamine Agonist)
3.	pramipexol (pramipexole)
4.	Bromocriptine (Parlodel)
5.	Dopamine (Intropin)
6.	Ergolines
7.	cabergoline
8.	N 0437
9.	ropinirole (Requip)
10.	U 95666E

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Aftercare (After-Treatment)
3.	Renal Dialysis (Hemodialysis)
4.	Oral Administration
5.	Transdermal Patch